Searchable abstracts of presentations at key conferences in endocrinology

ea0014p166 | (1) | ECE2007

Cabergoline suppression test in distinguishing the variability of response to dopamine agonists in prolactinomas

BADIU Corin , VOICU Daniela , Caragheorgheopol Andra , Hortopan Dan , Silvestro Luigi

Primary therapy in prolactinomas, the most frequent pituitary adenomas, consists in ergot derivatives dopamine agonists (bromocriptine or cabergoline) which lowers prolactin levels and shrink the tumour. Bromocriptine was the first drug used, but the therapeutic levels are attained after several days/weeks, therefore an acute suppression test is not possible. However, the biological response is variable and 10% of prolactinomas are resistant to medical therapy. In order to eva...

ea0020p538 | Growth and Developmental Endocrinology | ECE2009

Short stature in betathalassemia major: a multifactorial condition

Albu Alice , Zirnea Anca , Vladareanu Florentina , Voicu Daniela , Nitu Larisa , Florea Suzana , Fica Simona

Short stature is a frequent finding among patients with beta-thalassemia major, with a major impact on the quality of life and a multifactorial aetiology.Aim: To study the relationship between growth retardation of thalassemic patients and associated sistemic conditions and endocrine complications.Subjects and methods: Cross-sectional study on 59 patients with ╬▓thalassemia major who did not reach their final height, with a mea...